Longevity Health soars 58.82% on Nasdaq approval

On May 22, 2025, Longevity Health surged 58.82% in pre-market trading, marking a significant rise in its stock price.

Longevity Health Holdings has received approval from the Nasdaq Hearings Panel to continue its listing on Nasdaq, contingent on meeting initial listing requirements following its proposed merger with 20/20 Biolabs by September 2, 2025. This decision is part of a strategic plan that includes a 1-for-30 reverse stock split and the filing of an S-4 registration statement for the merger. The company is focused on extending human longevity and healthy aging through innovative products in regenerative bio-aesthetics, diagnostics, and nutrition.

The approval from Nasdaq has been a key driver for the surge in Longevity Health's stock price. The company's strategic initiatives, including the reverse stock split and the merger with 20/20 Biolabs, are aimed at complying with Nasdaq's rules and advancing its mission in the longevity solutions market. These developments have instilled confidence among investors, leading to a significant increase in the stock's value.